Trial Profile
Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Aug 2022 Results (data cutoff date: 22 May 2020) of updated analysis reporting survival outcome and long-term tolerability published in the Journal of Clinical Oncology
- 08 Jun 2021 Results assessing updated OS and long-term tolerability analysis, including subgroup analyses focusing on a type of EGFR mutation and metastatic sites, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 04 Nov 2019 Results published in the Journal of Clinical Oncology